JP7839554B2 - Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 - Google Patents

Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Info

Publication number
JP7839554B2
JP7839554B2 JP2022561542A JP2022561542A JP7839554B2 JP 7839554 B2 JP7839554 B2 JP 7839554B2 JP 2022561542 A JP2022561542 A JP 2022561542A JP 2022561542 A JP2022561542 A JP 2022561542A JP 7839554 B2 JP7839554 B2 JP 7839554B2
Authority
JP
Japan
Prior art keywords
sequence
kras
antisense oligonucleotide
nucleic acid
oligonucleotide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022561542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521383A (ja
JP2023521383A5 (https=
Inventor
ペコット，チャド
アザム，サルマ・エイチ．
Original Assignee
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/842,404 external-priority patent/US11180759B2/en
Application filed by ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル filed Critical ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Publication of JP2023521383A publication Critical patent/JP2023521383A/ja
Publication of JP2023521383A5 publication Critical patent/JP2023521383A5/ja
Application granted granted Critical
Publication of JP7839554B2 publication Critical patent/JP7839554B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022561542A 2020-04-07 2021-04-07 Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 Active JP7839554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/842,404 2020-04-07
US16/842,404 US11180759B2 (en) 2016-01-19 2020-04-07 Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
PCT/US2021/026147 WO2021207339A1 (en) 2020-04-07 2021-04-07 Methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras

Publications (3)

Publication Number Publication Date
JP2023521383A JP2023521383A (ja) 2023-05-24
JP2023521383A5 JP2023521383A5 (https=) 2024-04-09
JP7839554B2 true JP7839554B2 (ja) 2026-04-02

Family

ID=78024140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561542A Active JP7839554B2 (ja) 2020-04-07 2021-04-07 Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Country Status (4)

Country Link
EP (1) EP4100530A4 (https=)
JP (1) JP7839554B2 (https=)
CA (1) CA3169550A1 (https=)
WO (1) WO2021207339A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149557A4 (en) * 2020-05-13 2025-01-15 The University of North Carolina at Chapel Hill Nucleic acid ligand conjugates and use thereof for delivery to cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538678A (ja) 2007-09-18 2010-12-16 イントラドイグム コーポレーション Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103555722B (zh) * 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
EA201492004A1 (ru) * 2012-05-02 2015-08-31 Новартис Аг Органические композиции для лечения kras-ассоциированных заболеваний
WO2015164818A1 (en) * 2014-04-25 2015-10-29 Strike Bio, Inc. Multiple targeted rnai for the treatment of cancers
EP3307890A1 (en) * 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
WO2017127473A1 (en) * 2016-01-19 2017-07-27 The University Of North Carolina At Chapel Hill Methods and compositions using rna interference for inhibition of kras
EP3436585B1 (en) * 2016-04-01 2022-07-20 Avidity Biosciences, Inc. Kras nucleic acids and uses thereof
US20210115449A1 (en) * 2018-04-19 2021-04-22 Board Of Regents, The University Of Texas System Therapeutic modulation of tumor suppressors using exosomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538678A (ja) 2007-09-18 2010-12-16 イントラドイグム コーポレーション Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法

Also Published As

Publication number Publication date
JP2023521383A (ja) 2023-05-24
CA3169550A1 (en) 2021-10-14
WO2021207339A1 (en) 2021-10-14
EP4100530A4 (en) 2024-05-22
EP4100530A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CA3050265C (en) Methods and compositions using rna interference for inhibition of kras
US20220090088A1 (en) Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-Cas
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
KR20160097331A (ko) 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
US9290763B2 (en) Construction of bifunctional short hairpin RNA
US20220073923A1 (en) Methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras
CA2946407A1 (en) Multiple targeted rnai for the treatment of cancers
CA2717637A1 (en) Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide
JP2011507554A (ja) 遺伝子発現を増加させるための方法および組成物
CN116113697A (zh) 用于治疗癫痫的方法和组合物
KR20220119084A (ko) 폴리뉴클레오티드를 엑소솜에 전달하기 위한 핵산 구축물
JP7839554B2 (ja) Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物
CN115697416A (zh) 核酸配体偶联物及其用于向细胞递送的用途
US20240309384A1 (en) INVERTED CHIMERIC siRNA MOLECULES AND METHODS OF USE THEREOF
CN114306367B (zh) 一种含有C/EBPα-saRNA的组合物
US20250376679A1 (en) Methods and compositions for inhibition of irf4
WO2011065677A2 (ko) 암 치료용 약학 조성물
JP2026502888A (ja) エピジェネティック調節因子の新規阻害剤
US20130259926A1 (en) BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF
WO2024263883A2 (en) 5' antisense dna modifications to enhance rna interference activity
WO2016077566A1 (en) Modulation of alternative mdm2 splicing
WO2025245193A1 (en) Methods and compositions for inhibition of mutant gnaq and gna11
WO2025072604A1 (en) Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
JP2024510010A (ja) 癌療法
WO2024036343A2 (en) Synergistic nucleic acid based therapeutics and methods of use for treating genetic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260313

R150 Certificate of patent or registration of utility model

Ref document number: 7839554

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150